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Summary Measurements of transforming growth factor a (TGF-a) in cancer patients have produced
variable results. We have now used a specific radioimmunoassay (RIA) and a mitogenic assay to evaluate
TGF-a content of tumour and urine samples separated by an analytical HPLC system. Urine samples from
patients with breast tumours and from age matched controls gave TGF-a amounts ranging from 0 to
61.5ng24h-1 compared to urogastrone epidermal growth factor figures of 3.0-26.2jg24h-1. The quantities
of TGF-a in patient and control groups were not significantly different. The majority of breast tumour
extracts contained mitogenic material eluting from the HPLC system at the TGF-a calibration point.
Measurement by RIA of combined samples from each group showed that steroid receptor positive tumours
had a mean figure of 14.8ngg-1 tissue and steroid receptor negative 7.4ngg-1. Receptor positive tumours
from patients treated with an antioestrogen, tamoxifen citrate (Nolvadex), had 0.16ngg-1. Thus TGF-a is
found in tumours as a biologically active entity and in quantities sufficient to promote cell division. In
addition the observation that tamoxifen causes a significant reduction in the content of TGF-a may be an
additional beneficial action.
Mouse and human urogastrone-epidermal growth factors
(URO-EGF) were characterised many years ago (Savage et
al., 1972; Gregory, 1975) but their roles in normal physio-
logical processes remain to be established. As proven power-
ful mitogens for cells of many types it has frequently been
suggested that an association with abnormal growth might
emerge but again this has not been defined. In addition to
normal members of this growth factor family other 'trans-
forming' growth factors (TGF) have been identified. The
original property of inducing colony formation in suspension
from selected indicator cells (DeLarco & Todaro, 1978) has
been shown to be due to the synergistic action of two
different polypeptides, TGF-a and TGF-f3 (Anzano et al.,
1983). TGF-cx characterised from a human melanoma cell
line and a virally transformed rat cell line was clearly a
member of the URO-EGF family and also had a highly
conserved structure (Marquardt et al., 1983, 1984). TGF-a
was thought to be associated with malignancy leading to the
hypothesis of autocrine control in cancer (Sporn & Roberts,
1985). The human TGF-a gene is on chromosome 2 close to
the breakpoint in Burkitt's lymphoma (Brissenden et al.,
1985) and this suggests a mechanism whereby a normally
suppressed TGF-oa could be reactivated and contribute to
tumour progression.
A precursor molecule for TGF-a contains 160 amino acids
and a characteristic transmembrane sequence (Derynk et al.,
1984). Subsequent processing could account for the variety
of TGF-a species reported to be associated with tumours
(Bano et al., 1985), cell lines (Saloman et al., 1984; Dickson
et al., 1986) or urine extracts. Measurements of TGF-a in
urine samples using colony forming and radioreceptor assays
indicated TGF-a-like activity in 18/22 cancer patients com-
pared to 5/22 in controls (Sherwin et al., 1983). Later studies
on bulk processed urine found that immunoreactive TGF-a
was not detectable in the control preparation (Stromberg et
at., 1987), whereas the controls in a study of hepatocellular
carcinoma patients had large amounts of TGF-ax (Yeh et al.,
1987).
The aim of our studies was to compare the secretion of
TGF-a and URO-EGF in the urine of cancer patients
compared with controls. In addition, we wished to measure
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the levels of TGF-a in tumours and to test whether they are
affected by tamoxifen citrate. Fractionated urine samples
from cancer patients were measured by specific RIAs for
URO-EGF and TGF-oa. Tumour extracts were fractionated
and measured for the ability to stimulate mitogenesis in
fibroblasts and also by RIA. The results fail to show
differences in the TGF-a output into urine of cancer patients
compared to controls. However, TGF-a produced by breast
tumours is considerably reduced after treatment of patients
with the antioestrogen.
Materials and methods
Biosynthetic URO-EGF and TGF-a were derived from
synthetic genes expressed in E. coli and were purified as
described previously (Franklin et al., 1986; Gregory et al.,
1988) to give the human sequence 53 and 50 amino acid
residue polypeptides.
Radioimmunoassay of URO-EGF was carried out as
described previously (Gregory et al., 1988) using a rabbit
antibody to the growth factor and double antibody sepa-
ration. The standard curve range was 20pg to 10ng and
10pg TGF-a gave a reading of 40pg URO-EGF.
Radioimmunoassay of TGF-a was established as follows.
Sheep were immunised with TGF-oc (250,ug) in 2ml saline:
Freunds complete adjuvant, 1: 1, given subcutaneously. One
month later the same amount was given in incomplete
adjuvant and subsequently monthly injections of 25-50pg in
saline were given s.c. The best of the sheep sera bound
radiolabelled TGF-a at only a 1:2,000 dilution.
An affinity column was prepared from TGF-a and acti-
vated carboxyhexyl sepharose (Pharmacia) by the procedure
described by the manufacturers. Sheep antiserum was centri-
fuged at 20,000g for 30min and then recycled through a
limited amount of affinity support for 48h at 40C which
absorbed about 80% of the binding capacity of the serum.
The column was exhaustively washed with phosphate buf-
fered saline (PBS) and the absorbed antibody eluted using a
pulse of 1 M acetic acid which was collected directly into an
excess of 1 M tris/HCl at pH8.0. The eluate was concentrated
over a YM 30 membrane (Amicon Corporation) and con-
verted to a PBS solution. The assay was conducted exactly
as for URO-EGF using the purified antibody at 1:2,000
compared to starting serum. The range of TGF-a measured
N
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was from 10pg to 5ng (Figure 1) and 10pg URO-EGF gave
a reading of 40pg TGF, i.e. same low cross reactivity as the
URO-EGF assay.
The mitogenic potential of samples was assessed by
observing the stimulation of radiolabelled thymidine uptake
into confluent monolayers of NIH 3T3 cells in 0.5% fetal
calf serum as previously described (Gregory et al., 1988). We
had found that radiolabel uptake over 24h paralleled the
dose-response curves for URO-EGF and TGF-a in causing
increase in actual cell numbers over 7 days. Samples were
measured in triplicate.
Aliquots of 40ml urine taken from 24h collections from
patients with advanced breast tumours and age matched
controls were centrifuged at 20,000g for 30min at 40C and
then concentrated over a YM2 ultrafiltration membrane
(Amicon Corporation). The concentrate (approx. 1 ml) was
applied directly to a reverse phase HPLC column (Vydac
C18, 25xO.46cm). The elution gradient of 0.1% trifluoro-
acetic acid in water to 0.1% trifluoroacetic acid in aceto-
nitrile was as defined for the separation of TGF-a and
URO-EGF peptides (Gregory et al., 1988). The fractions
were dried by vacuum centrifugation (Univap) and then
redissolved in PBS (1ml). Aliquots of 2x250p1 were taken
for measurement of TGF-a by radioimmunoassay and
2 x 5Opl for URO-EGF. Accurate quantitation of total
TGF-a was obtained by combining the remaining samples of
fractions 43-48 and using fractions 51-56 as control. Each
pooled group of urine sample was measured in duplicate
(2 x 1 ml) and the relevant internal control subtracted. Pro-
cessing of patient and control urines was carried out in
parallel. The 24h total (Table I) is thus given by multiplying
the observed amount of TGF-cx by 6/40 x 24h urine volume.
Tumour samples obtained at surgery from a different
group of patients to those providing urine samples were
immediately frozen in liquid nitrogen and maintained at that
temperature for longer term storage at -80°C. Receptors for
oestrogen and progesterone were measured using the
dextran-coated charcoal technique as described previously
(Barnes et al., 1977). For both ER and PR the samples were
regarded as positive if 5 or more fmol per mg of cytosol
protein was measured.
The tissue samples of about 1 g were cut into small pieces
and immediately blended (Ilado) for 30s at 4°C with 5ml
buffer which comprised 20mm Hepes, 2mm ethylene dia-
mine tetra acetic acid, 0.5mM phenyl methyl sulphonyl
fluoride made to pH 7.4.
The homogenate was centrifuged for 15min at 4°C at
800g and the opaque supernate spun again at 40,000g for
60min at 4°C. The residue from the latter was retained for
V
Q 0
a)
n
LL (9
I-
-o
)
a)
.0
0
0)
Log1o amount of T.G.F-a (ng)
Figure 1 The standard curve for the radioimmunoassay for
TGF-ac.
Table I Measurements of TGF-a and URO-EGF in urine
TGF-a measured in
combined HPLC
fractions TGF-a total URO-EGF total
(ngml-1) (ng 24h-1) (jig 24h-1)
Breast cancer patient
1 1.000 61.5 3.76
2 0.146 12.9 3.02
3 0.030 10.1 9.36
4 0.021 * 5.3 5.94
5 0.119 18.1 5.63
Control
1 0.001 0.0 21.08
2 0.059 26.3 16.58
3 0.050 13.5 10.57
4 0.086 14.2 26.22
5 0.028 7.1 19.07
receptor studies and the supernate diluted with two volumes
of cold absolute ethanol and immediately centrifuged again
at 1,250g, 30min, 4°C. The supernatant was poured into
four volumes cold ethyl acetate and the mixture was kept at
4°C for 16h. Removal of the organic phase left a very small
aqueous phase which was washed with 2ml M acetic acid
solution into a small flask for lyophilysation. The dried
product was taken into 0.1% aqueous trifluoroacetic acid
(0.5ml), centrifuged to remove trace insoluble materials and
then applied to the reverse phase HPLC system as for the
urine samples. The individual dried fractions were reconsti-
tuted in 200pl Dulbecco minimum essential medium
(DMEM) for the assays.
MCF-7 cells were grown to a cell population of approx.
109 in DMEM with 10% fetal calf serum and then main-
tained in serum-free medium for 3 days. The medium
(1,500ml) was filtered through a 0.45pm filter and then
concentrated over a YM2 membrane to 5ml. This was made
molar in acetic acid, centrifuged and applied to a column
(100 x 1.5cm) of BioGel P-30 (Bio-Rad) in the same solvent.
Fractions (2.4ml) were individually monitored for TGF-a by
RIA. Combined lyophilysed fractions were then run on the
usual HPLC system.
Results
The TGF-ai profile from MCF-7 cells (Figure 2) showed that
the major product ran in the same position as the recombi-
nant synthetic TGF-cx (S-TGF-ca made accordifig to the
published human structure (Marquardt et al., 1983)). Further-
more, this also ran in the S-TGF-ax position in the usual
HPLC system (e.g. Figure 3) after purification by affinity
chromatography. The higher molecular weight component
(approximately 30-40kD) by its position on the P-30 column
only, ran three or four fractions later on HPLC and as a
broader peak. There was no indication of heterogeneity
beyond these two components.
The detailed analytical profile for the urine of qne
tumour-bearing patient is shown in Figure 3 (patient no. 5,
Table I). There is minimal cross-reaction between TGF-a
and URO-EGF and the optical density evaluation at 206nm
(not shown) indicates sharp resolution by the HPLC column
used. This was confirmed by the S-TGF-c and S-URO-EGF,
subsequently used for calibration, being restricted totally to
two fractions. The same column was used throughout for
urine samples and gave peaks for TGF-o at fraction 44 and
for URO-EGF (53 residue) at fraction 62. A second peak
discernible at fraction 47 coincided with the higher molecular
weight species from the MCF-7 extract.
The URO-EGF pattern was more complex and resolved
normally into at least twelve definable components (unpub-
lished data). The main components were the 53 residue
protein at fraction 62, the known 52 residue protein atTRANSFORMING GROWTH FACTOR ac 607
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Figure 2 Measurement of TGF-ax by RIA in fractions from a
Bio-Gel P-30 column of concentrated MCF-7 cell medium.
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Figure 3 Growth factor content (per ml fraction) measured by
radioimmunoassay of a concentrated urine sample - separated by
HPLC, from a patient with breast cancer.
fraction 69 and a component at fraction 65 which has been
only partially characterised. The latter peak occurred in all
five urine samples from tumour-bearing patients but to no
significant extent in the controls.
Because individual fractions gave TGF-ax measurements at
the less sensitive part of the RIA curve, combined samples,
fractions 43-48, were used to give accurate determinations
for each patient. Control measurements of fractions 51-56
varied from 6 to 26pgml-1. The figures for the 10 urine
samples are given in Table I. All five patients had definable
TGF-ax concentrations, as did four of the five controls and
there was no significant difference between the groups. Total
URO-EGF levels were about 1,000-fold greater than TGF-a
but the amounts produced by the tumour-bearing patients
were substantially lower compared with controls in every
case (P<0.005 for the group mean values). No correlation
existed between the amounts of TGF-a and URO-EGF
extracted. Other studies have reported increased URO-EGF
output relative to creatinine in patients with tumours
(Uchihashi et al., 1983) but further measurements are needed
to define if these differences relate to particular types of
tumour.
The tumour extracts were prepared using the solvent-based
system, which in trial experiments gave 50-60% recovery of
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Figure 4 Uptake of tritiated thymidine by mouse fibroblasts by
HPLC fractions of the extract of a breast tumour. This tumour
(0.65g), which was negative for all three receptors, was processed
as described then each fraction was reconstituted in 200 1
medium and assayed in triplicate using aliquots of 20ul.
TGF-a and URO-EGF from starting tissue after HPLC
fractionation. The final separation used the same gradient
elution as for the urine samples but a different reverse phase
column in which retrospective calibration with S-TGF-c and
S-URO-EGF placed them at fractions 39 and 51. The profile
of mitogenic activity shown by a tumour extract is given
(Figure 4) with these reference points indicated. In each
assay with 3T3 cells, thymidine uptake was confirmed using
S-URO-EGF with a peak effect of 15-20 x background
counts at 0.5-1 ngml- . S-URO-EGF and S-TGF-a were of
similar potency in this respect (Gregory et al., 1988). In the
sample shown (Figure 4), stimulatory activity was observed
at the S-TGF-a position. Although the profile of mitotic
activity varied widely for the tumour extracts, 4/5 samples of
oestrogen (ER), progesterone (PR) receptor positive
tumours, 4/5 of ER, PR negative tumours and also 4/5 of
the patients pretreated with tamoxifen citrate showed detect-
able activity at fraction 39. The treated samples appeared to
have less stimulatory capacity but this was not quantifiable
in the mitogenic assays.
Because of limited amounts of each fraction, which were
also used for other assays, aliquots of 20pl from fractions
37-41 from each group of tumours were combined for
accurate RIA measurement. The TGF-ax content of the five
ER and PR positive tumours was 14.8 ngg-1, for the ER
and PR negative tumours it was 7.4ngg-1 and for the ER
and PR positive tumours when the patients had received
tamoxifen citrate it was 0.16ngg-1. Although they could not
be measured with statistical accuracy, the mitogenic activities
of the TGF-cx peaks were in keeping with the RIA
quantitation.
The remaining fractions, 42 to the end, were combined in
groups of five and assayed for TGF-c and URO-EGF
content. None of the latter was found in any sample,
particularly in the calibrated region. TGF-a immuno-
reactivity did extend to fractions 42-46 but it was not
possible to show clearly that this was the higher molecular
weight species found in MCF-7 extracts or urine samples
because there was insufficient material to show stimulation
in the 3T3 cell assay.
Discussion
The presence of TGF-a in the conditioned medium of MCF-
7 cells has been reported previously (Dickson et al., 1986).
Gel chromatography of the concentrate of serum-free
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medium gives two components of differing size. The higher
molecular weight species appears to be of 30-40kD which is
greater than expected for a 180 amino acid precursor,
whereas the lower molecular weight species synchronises on
gel chromatography and subsequent HPLC systems with
biosynthetic TGF-a prepared in accord with the published
structure for a 50 amino acid peptide (Derynck et al., 1984).
Both components were measured using an RIA system with
an antibody raised to the synthetic TGF-a and purified using
an affinity column of the same peptide. The lower molecular
weight material from MCF-7 cells, biosynthetic material and
urine run as a single sharp band on an HPLC system
whereas the higher molecular weight MCF-7 species appear
about four fractions later as a somewhat broader band.
All samples of urine from tumour-bearing patients con-
tained measurable TGF-a of the defined molecular species
with indications that a higher molecular weight TGF-a is
also present. In four of the five control samples TGF-a was
measurable also and using larger amounts of control urine,
not detailed here, both the 50 amino acid peptide and the
higher molecular weight species could be defined. Thus, we
did not see in this patient and control population the major
increase in TGF-a previously reported. Nor can we agree
that it is absent in control urine using immunoassay and
mitogenesis as our criteria rather than receptor binding and
colony forming assays which gave values of 178pgml-1 in
patient urine but undetectable values in controls (Stromberg
et al., 1987). The receptor assay responds to all members of
the EGF family and colony formation is induced by many
disparate molecules.
Some reports describe increases of URO-EGF in tumour-
bearing patients (Uchihashi et al., 1983). Output was related
to creatinine but we have preferred to relate output to
weight and we have failed to observe any increase in
patients. Indeed, in the present studies all five tumour
patients had a significantly lower total output than the
controls. Moreover, detailed analysis of the molecular com-
ponents of the mixture showed the presence of a structural
variant falling between the 53 and 52 residue component on
the HPLC trace which is not obvious in the controls. The
relevance of this observation is as yet unclear.
Carrying out detailed extraction and measurement pro-
cedures on each tumour inevitably meant that relatively
small numbers could be evaluated so group sizes of five well
characterised tumours were chosen. The process devised for
processing the tumour tissue was based upon knowledge of
the physical properties of known agents such as URO-EGF
and TGF-a. Model experiments with these two growth
factors gave a final recovery of over 50% and it was thus
anticipated that any small molecular factor of this family
would be represented in the HPLC fractions. It was not
known whether different forms, e.g. high molecular weight
precursors, would also be found in the final extract. With
this proviso the majority of the 15 tumours gave a peak of
'mitogenic' activity in the exact position defined by synthetic
TGF-a (Figure 4). Small amounts of sample prevented dose-
response curve evaluation of these samples although the
stimulatory properties were less in the tamoxifen citrate-
treated patient samples. This was confirmed by precise RIA
evaluation of the TGF-a content of combined relevant
fractions from each group. No clearly separated regions of
TGF-oc like immunoreactivity could be detected across the
HPLC distribution nor was it possible to measure any
human URO-EGF with the immunoassay which was capable
of measuring down to 1Opg per sample. Whether the
reduced amount of TGF-ax after anti-oestrogen treatment is a
simple consequence of the treatment or is directly involved in
the established antitumour effect of the drug in these
patients remains to be proven. In the patients with receptor
negative tumours, the amounts of TGF-a did not differ
substantially from the receptor positive ones. Studies are
under way to observe the effect of tamoxifen citrate upon
tumours in these patients.
Several groups have shown the existence of mRNA for
TGF-a in both carcinomas and cell lines and the secretion of
immunoreactive TGF-a in the medium from these cells
(Derynk et al., 1987) and, of course, the receptor is amplified
in many tumour cell lines. In our studies we have found
clear evidence of an active mitogen corresponding to TGF-a
in the majority of breast tumours and that this is present to
a reduced extent in tumours from patients treated with
tamoxifen citrate. URO-EGF could not be measured in any
of these samples although it is known to be present in high
concentrations in all biological fluids studied (Gregory,
1985). Conversely, in the urine of both controls and patients
TGF-a occurred to the same extent but the URO-EGF
amounts were lower in the patients.
The mitogenic activities observed at higher fraction
numbers do occur with high frequency in the extracts of all
breast tumours (25 examined). They are not related immuno-
genically to EGF or TGF-a nor do they relate either in
HPLC position or activity in our 3T3 cells with many known
agents, e.g. TGF-f, IGF-1, bombesin, etc. At present, there-
fore, they represent novel growth factors meriting further
exploration.
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